ABIVAX
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.
ABIVAX
Industry:
Biotechnology
Founded:
2013-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.abivax.com
Total Employee:
11+
Status:
Active
Contact:
+33(0)1 53 83 08 41
Email Addresses:
[email protected]
Total Funding:
96.2 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Benchmark Holdings
Benchmark Holdings, a pioneering bioagtech company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
CareDx
CareDx is a novel molecular diagnostics company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - Abivax
Invus
Invus investment in Post-IPO Equity - Abivax
TCG Crossover
TCG Crossover investment in Post-IPO Equity - Abivax
Truffle Capital
Truffle Capital investment in Post-IPO Equity - Abivax
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Abivax
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Abivax
Kreos Capital
Kreos Capital investment in Post-IPO Debt - Abivax
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - Abivax
Kreos Capital
Kreos Capital investment in Post-IPO Debt - Abivax
Key Employee Changes
| Date | New article |
|---|---|
| 2021-03-01 | Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.abivax.com Semrush global rank: 3.09 M Semrush visits lastest month: 5.19 K
- Host name: 104.21.59.143
- IP address: 104.21.59.143
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Abivax"
About Abivax
Abivax is a clinical-stage biotechnology company focused on harnessing the body’s natural regulatory mechanisms through enhanced expression of microRNA-124. See details»
Our Pipeline - Abivax
Abivax is looking forward to evolving into a commercial-stage company through opportunities to potentially harness the novel mechanism of action of obefazimod and beyond. See details»
Abivax - Wikipedia
Abivax focuses on the treatment of inflammatory bowel diseases, namely ulcerative colitis (UC) and Crohn’s disease (CD). Its lead drug candidate, obefazimod, is an oral, first-in-class, small molecule that has demonstrated safety and tolerability as well as profound anti-inflammatory activity in preclinical as well as clinical trials in UC. See details»
Investor Relations | Abivax
Jun 2, 2025 The Investor Relations website contains information about Abivax's business for stockholders, potential investors, and financial analysts. See details»
Abivax - LinkedIn
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with ... See details»
Our Mission - Abivax
Abivax now has global headquarters in Paris, France and US headquarters in the greater Boston area. Clinical trials for obefazimod are being conducted throughout the world as shown by shaded areas on the map. We anticipate … See details»
Company History - Abivax
Abivax has a history of following the science and recognizing its potential to address unmet needs, which enables continuous exploration and future possibilities. See details»
Abivax - Crunchbase Company Profile & Funding
Abivax is a clinical-stage biotechnology company, that mobilizes the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Their aim is to use Abivax's drug development … See details»
ABIVAX Société Anonyme (ABVX) Company Profile & Description
2 days ago Company profile for ABIVAX Société Anonyme (ABVX) stock, with a description, list of executives, contact details and other key facts. See details»
Abivax Announces Launch of Public Offering
2 days ago Abivax Announces Launch of Public Offering PARIS, France , July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA ( Euronext Paris : FR0012333284 – ABVX) (“ Abivax ” or the “ … See details»
Our Leadership - Abivax
Abivax has an experienced leadership team with expertise in the scientific development and commercialization of therapeutics for chronic inflammatory diseases. See details»
ABIVAX Société Anonyme Company Description - Stock Analysis
Dec 16, 2024 Company profile for ABIVAX Société Anonyme (EPA: ABVX) with a description, list of executives, contact details and other key facts. See details»
Abivax 2025 Company Profile: Stock Performance & Earnings
Information on stock, financials, earnings, subsidiaries, investors, and executives for Abivax. Use the PitchBook Platform to explore the full profile. See details»
Abivax Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 Abivax has 5 employees across 2 locations. See insights on Abivax including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. See details»
Abivax SA Company Profile - Overview - GlobalData
Abivax SA: Overview Abivax SA (Abivax) is a biopharmaceutical company that primarily focuses on the discovery and development of novel treatments for chronic inflammatory diseases. The … See details»
Abivax provides operational and key program update — Sofinnova …
Jul 15, 2024 Abivax announces the appointment of Dr. Sylvie Grégoire as Chair of the Board of Directors effective immediately. Dr. Grégoire is a distinguished pharmaceutical and biotech … See details»
ABIVAX Société Anonyme (ABVX) - Yahoo Finance Canada
Find the latest ABIVAX Société Anonyme (ABVX) stock quote, history, news and other vital information to help you with your stock trading and investing. See details»
Abivax Presents First Quarter 2025 Financial Results
On January 23, 2025 in a press release titled “Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual … See details»
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel …
2 days ago Abivax SA (NASDAQ:ABVX) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced overwhelmingly positive topline results from its Phase 3 … See details»
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially ...
2 days ago Shares of Abivax hit the stratosphere Wednesday after the firm unveiled "potentially disruptive" results for its ulcerative colitis drug. See details»